SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
09 juil. 2024 02h00 HE
|
SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
14 févr. 2024 07h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
09 févr. 2024 07h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
DIG raises $65 million in Series F Funding Round from New & Existing Investors with Progressive Vision
27 oct. 2021 10h46 HE
|
DIG
New York, NY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DIG, the vegetable-centric, multi-format restaurant group announces its series F raise of $65 million, returning to growth with an industry-leading...
Evergold Signs Definitive Agreement to Option the Rockland Gold-Silver Property, Nevada
16 févr. 2021 07h00 HE
|
Evergold Corp.
TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evergold Corp. (TSX-V: EVER, OTC: EVGUF, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce, further to its news release dated January 11,...
Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives
25 sept. 2020 09h00 HE
|
Vitality Biopharma, Inc
CLEVELAND, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of...
Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants
10 oct. 2018 16h01 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
05 oct. 2018 08h10 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
04 oct. 2018 16h01 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to...
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
22 janv. 2018 18h59 HE
|
Histogenics Corporation
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an...